Recently, a preclinical trial using a DNA vaccine against FAP synergized with anticancer immune therapy targeting Prostate Membrane Antigen (PMSA) in tumor-bearing mice model for prostate cancer [242]. The gene discussed is FAP; the disease is neoplasm.